STAT3 knockdown in B16 melanoma by siRNA lipopolyplexes induces bystander immune response in vitro and in vivo

Translational Oncology

Volumn 4, Issue 3, 2011, Pages 178-188

  Alshamsan, Aws ^a,b   Hamdy, Samar ^b   Haddadi, Azita ^c   Samuel, John ^b   El Kadi, A O S ^b   Uludaǧ, Hasan ^b   Lavasanifar, Afsaneh ^b  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; GAMMA INTERFERON; INTERLEUKIN 12; POLYETHYLENEIMINE; SMALL INTERFERING RNA; STAT3 PROTEIN; STEARIC ACID; TUMOR NECROSIS FACTOR ALPHA;

ALLOIMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BYSTANDER EFFECT; CANCER GROWTH; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL INFILTRATION; CONTROLLED STUDY; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE SILENCING; IMMUNE RESPONSE; LYMPHOCYTE; MALE; MELANOMA; MIXED LYMPHOCYTE REACTION; MOUSE; NATURAL KILLER CELL; NONHUMAN; PROTEIN TARGETING; SPLEEN CELL;

EID: 79957924781     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.11100     Document Type: Article

References (43)

1. Hanahan D and Weinberg RA (2000). The hallmarks of cancer. Cell 100(1), 57-70.
2. Pardoll D (2003). Does the immune system see tumors as foreign or self? Annu Rev Immunol 21, 807-839.
3. Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, Zhang S, Bhattacharya R, Gabrilovich D, Heller R, Coppola D, et al. (2004). Regulation of the innate andadaptive immune responses by STAT-3 signaling in tumor cells. Nat Med 10(1), 48-54.
4. Kortylewski M, Jove R, and Yu H (2005). Targeting STAT3 affects melanoma on multiple fronts. Cancer Metastasis Rev 24(2), 315-327.
5. Cheng F, Wang HW, Cuenca A, Huang M, Ghansah T, Brayer J, Kerr WG, Takeda K, Akira S, Schoenberger SP, et al. (2003). A critical role for STAT3 signaling in immune tolerance. Immunity 19(3), 425-436.
6. Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, Pilon-Thomas S, Niu G, Kay H, Mule J, Kerr WG, et al. (2005). Inhibiting STAT3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 11(12), 1314-1321.
7. Buettner R, Mora LB, and Jove R (2002). Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 8, 945-954.
8. Hirano T, Ishihara K, and Hibi M (2000). Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene 19(21), 2548-2556.
9. Ivanov VN, Bhoumik A, Krasilnikov M, Raz R, Owen-Schaub LB, Levy D, Horvath CM, and Ronai Z (2001). Cooperation between STAT3 and c-jun suppresses Fas transcription. Mol Cell 7(3), 517-528.
10. Kortylewski M and Yu H (2007). STAT3 as a potential target for cancer immunotherapy. J Immunother 30(2), 131-139.
11. Kortylewski M and Yu H (2008). Role of STAT3 in suppressing anti-tumor immunity. Curr Opin Immunol 20(2), 228-233.
12. Yu H, Kortylewski M, and Pardoll D (2007). Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 7(1), 41-51.
13. Xu Q, Briggs J, Park S, Niu G, Kortylewski M, Zhang S, Gritsko T, Turkson J, Kay H, Semenza GL, et al. (2005). Targeting STAT3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene 24(36), 5552-5560.
14. Nefedova Y, Nagaraj S, Rosenbauer A, Muro-Cacho C, Sebti SM, and Gabrilovich DI (2005). Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the Janus-activated kinase 2/signal transducers and activators of transcription 3 pathway. Cancer Res 65(20), 9525-9535.
15. Cejka D, Losert D, and Wacheck V (2006). Short interfering RNA (siRNA): tool or therapeutic? Clin Sci (Lond) 110(1), 47-58.
16. Hede K (2005). Blocking cancer with RNA interference moves toward the clinic. J Natl Cancer Inst 97(9), 626-628.
17. Thomas M, Lu JJ, Chen J, and Klibanov AM (2007). Non-viral siRNA delivery to the lung. Adv Drug Deliv Rev 59(2-3), 124-133.
18. Alshamsan A, Hamdy S, Samuel J, El-Kadi AO, Lavasanifar A, and Uludag H (2010). The induction of tumor apoptosis in B16 melanoma following STAT3 siRNA delivery with a lipid-substituted polyethylenimine. Biomaterials 31(6), 1420-1428.
19. Alshamsan A, Haddadi A, Incani V, Samuel J, Lavasanifar A, and Uludag H (2009). Formulation and delivery of siRNA by oleic acid and stearic acid modified polyethylenimine. Mol Pharm 6(1), 121-133.
20. Lutz MB, Kukutsch N, Ogilvie AL, Rossner S, Koch F, Romani N, and Schuler G (1999). An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 223(1), 77-92.
21. Alshamsan A, Hamdy S, Das S, Lavasanifar A, Samuel J, and El-Kadi AO (2010). Bone marrow derived dendritic cells are more suitable than dendritic cell line DC2.4 to study tumor-mediated suppression of DC maturation through STAT3 hyperactivation. J Pharm Pharmaceut Sci 13(1), 21-26.
22. Al Zaid Siddiquee K and Turkson J (2008). STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res 18(2), 254-267.
23. Wang W, Edington HD, Rao UN, Jukic DM, Wang H, Shipe-Spotloe JM, and Kirkwood JM (2008). STAT3 as a biomarker of progression in atypical nevi of patients with melanoma: dose-response effects of systemic IFNα therapy. J Invest Dermatol 128(8), 1997-2002.
24. Niu G, Bowman T, Huang M, Shivers S, Reintgen D, Daud A, Chang A, Kraker A, Jove R, and Yu H (2002). Roles of activated Src and STAT3 signaling in melanoma tumor cell growth. Oncogene 21(46), 7001-7010.
25. Niu G, Heller R, Catlett-Falcone R, Coppola D, Jaroszeski M, DaltonW, Jove R, and YuH(1999). Gene therapy with dominant-negative STAT3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res 59(20), 5059-5063.
26. Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, Zhang S, Wang T, Sinibaldi D, Coppola D, et al. (2002). Constitutive STAT3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21(13), 2000-2008.
27. Xie TX, Wei D, Liu M, Gao AC, Ali-Osman F, Sawaya R, and Huang S (2004). STAT3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene 23(20), 3550-3560.
28. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernández-Luna JLF, Nuñez G, et al. (1999). Constitutive activation of STAT3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10, 105-115.
29. Niu G, Shain KH, Huang M, Ravi R, Bedi A, Dalton WS, Jove R, and Yu H (2001). Overexpression of a dominant-negative signal transducer and activator of transcription 3 variant in tumor cells leads to production of soluble factors that induce apoptosis and cell cycle arrest. Cancer Res 61(8), 3276-3280.
30. Rass K and Hassel JC (2009). Chemotherapeutics, chemoresistance and the management of melanoma. G Ital Dermatol Venereol 144(1), 61-78.
31. Segura E and Villadangos JA (2009). Antigen presentation by dendritic cells in vivo. Curr Opin Immunol 21(1), 105-110.
32. Trombetta ES and Mellman I (2005). Cell biology of antigen processing in vitro and in vivo. Annu Rev Immunol 23, 975-1028.
33. Yang Y and Wilson JM(1996). CD40 ligand-dependent T cell activation: requirement of B7-CD28 signaling through CD40. Science 273(5283), 1862-1864.
34. Johnson-Leger C, Christensen J, and Klaus GG (1998). CD28 co-stimulation stabilizes the expression of the CD40 ligand on T cells. Int Immunol 10(8), 1083-1091.
35. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, et al. (1997). Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277(5327), 818-821.
36. Schumacher LY, Vo DD, Garban HJ, Comin-Anduix B, Owens SK, Dissette VB, Glaspy JA, McBride WH, Bonavida B, Economou JS, et al. (2006). Immunosensitization of tumor cells to dendritic cell-activated immune responses with the proteasome inhibitor bortezomib (PS-341, Velcade). J Immunol 176(8), 4757-4765.
37. Martin-Fontecha A, Lanzavecchia A, and Sallusto F (2009). Dendritic cell migration to peripheral lymph nodes. Handb Exp Pharmacol 188(I), 31-49.
38. Onishi H, Kuroki H, Matsumoto K, Baba E, Sasaki N, Kuga H, Tanaka M, Katano M, and Morisaki T (2004). Monocyte-derived dendritic cells that capture dead tumor cells secrete IL-12 and TNF-α through IL-12/TNF-α/NF-κB autocrine loop. Cancer Immunol Immunother 53(12), 1093-1100.
39. Trinchieri G (2003). Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3(2), 133-146.
40. Brunner C, Seiderer J, Schlamp A, Bidlingmaier M, Eigler A, Haimerl W, Lehr HA, Krieg AM, Hartmann G, and Endres S (2000). Enhanced dendritic cell maturation by TNF-α or cytidine-phosphate-guanosine DNA drives T cell activation in vitro and therapeutic anti-tumor immune responses in vivo. J Immunol 165(11), 6278-6286.
41. Gabrilovich DI, Corak J, Ciernik IF, Kavanaugh D, and Carbone DP (1997). Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin Cancer Res 3(3), 483-490.
42. Schoenborn JR and Wilson CB (2007). Regulation of interferon-gamma during innate and adaptive immune responses. Adv Immunol 96, 41-101.
43. Kakuta S, Tagawa Y, Shibata S, Nanno M, and Iwakura Y (2002). Inhibition of B16 melanoma experimental metastasis by interferon-γ through direct inhibition of cell proliferation and activation of antitumour host mechanisms. Immunology 105(1), 92-100.